Two injections a year against HIV. The science is settled; the price is the story
A twice-yearly injection that prevented every infection in its main trial is the biggest HIV-prevention development in years. What the WHO has actually said is verified; whether the promised $40 price reaches African clinics is the part still to prove.
Key points
- The WHO recommended twice-yearly lenacapavir for HIV prevention on 14 July 2025.
- In the PURPOSE 1 trial (South Africa and Uganda), zero infections among 2,134 participants.
- The FDA had already approved it in June 2025.
- A generics plan aims for about $40 per person per year from 2027 — announced, not yet delivered.
What happened
HIV prevention has long depended on daily pills that people must remember and carry. Lenacapavir is different: an injection taken twice a year. In the PURPOSE 1 trial, run in South Africa and Uganda among more than 2,000 participants, there were zero infections among those on the drug. The US Food and Drug Administration approved it in June 2025, and in July 2025 the World Health Organization recommended it as an additional prevention option in new guidelines released alongside the IAS 2025 conference in Kigali.
The hard part is price. The branded product carries a US list price far beyond most African health systems. In September 2025 a partnership involving the Gates Foundation and Unitaid announced an aim to supply generics at around $40 per person per year from 2027 in up to 120 countries. An aim is not a delivery — which is why that claim below is still Not yet verified, even though the WHO recommendation itself is solid.
Claim by claim
Why this label: WHO's news release of 14 July 2025, issued around the IAS 2025 conference in Kigali: twice-yearly injectable lenacapavir (LEN) is recommended as an additional pre-exposure prophylaxis choice.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why this label: PURPOSE 1, conducted in South Africa and Uganda: zero infections among 2,134 participants on lenacapavir — the result the FDA used for its June 2025 approval.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why this label: A partnership reported in September 2025 aims for generic supply at around $40 per person per year from 2027 in up to 120 countries. That is an announced plan — doses have not yet been delivered at that price.
On the ladder: the evidence so far sits low — early, single or social sources. We publish the claim as a claim, never as fact.
What we know / what we don't know yet
What we know
- The WHO recommendation and its date (14 July 2025).
- The PURPOSE 1 trial result: zero infections.
- The FDA approval (June 2025) and the announced generics aim.
What we don't know yet
- Whether generic doses actually arrive at $40 in African countries from 2027.
- How quickly health systems can deliver a twice-yearly injection at scale.
Why it matters
Africa carries most of the world's new HIV infections — 1.3 million people acquired HIV in 2024 alone, by WHO's count. A prevention method that needs two clinic visits a year could change uptake completely, but only if the price promise survives contact with reality.
Update history
No silent edits. Every change is written here, with its time.
- Latest
Story published with the WHO guideline as the primary source.